Moleculin Biotech (MBRX) Stock: Buy, Sell, or Hold?
MBRX - Moleculin Biotech, Inc.
$0.72
-0.11 (-13.85%)
▼
5d:
+5.85%
30d:
+36.92%
90d:
-73.52%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When MBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MBRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MBRX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MBRX is currently trading at $0.71, which is considered extended relative to its 30-day fair value range of $0.47 to $0.71.
Technical Outlook: Technically, MBRX is in a strong downtrend. Immediate support is located at $0.62, while resistance sits at $0.90. Short-term momentum is weak, with the stock down 13.8% recently.
Market Sentiment: MBRX scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+1578.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MBRX is in a strong downtrend. Immediate support is located at $0.62, while resistance sits at $0.90. Short-term momentum is weak, with the stock down 13.8% recently.
Market Sentiment: MBRX scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+1578.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.47 -
$0.71
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-13.8%)
- BULLISH: Trading 1578.3% below Wall St target ($12.00)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.47 -
$0.71
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$0.90
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.61
Wall Street Target
$12.00
(+1578.3%)
Share & Embed Analysis
Last updated: September 13, 2026 3:29 PM ET
Data refreshes hourly during market hours. Next update: 4:29 PM
Data refreshes hourly during market hours. Next update: 4:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
